Key result
Ticlopidine reduced platelet-derived microparticles and platelet CD63 in patients with connective tissue diseases.
Why the study?
Does ticlopidine reduce platelet-derived microparticles and platelet activation in patients with connective tissue diseases and peripheral circulation disorders?
Observational (n=16)
Does ticlopidine reduce platelet-derived microparticles and platelet activation in patients with connective tissue diseases and peripheral circulation disorders?
Ticlopidine reduces platelet-derived microparticles and platelet activation in patients with connective tissue diseases and peripheral circulation disorders, suggesting potential to inhibit PMP-dependent vascular damage.
Answers are grounded in this paper and cite their sources.
Supports hypothesis of vascular protection in connective tissue diseases; hypothesis-generating, needs randomized confirmation before practice change.
We evaluated the plasma concentrations of platelet activation markers and platelet-derived microparticles (PMP) in patients with connective tissue diseases complaining of peripheral circulation disorders (n = 16) and studied the effect of ticlopidine hydrochloride (ticlopidine) on PMP generation. There were significant differences in the levels of PMP and a platelet activation marker between before and after treatment with ticlopidine (PMP: 695 +/- 393 vs. 354 +/- 206/10(4) platelets, p < 0. 01; platelet CD63: 9.13 +/- 5.64 vs. 5.22 +/- 2.74%, p < 0.05). On the other hand, markers of vascular endothelium, such as vascular endothelium-derived small vesicles and serum thrombomodulin levels, were not affected by the administration of ticlopidine. Levels of cytokines and soluble adhesion molecules remained unchanged by ticlopidine administration. These findings suggest that ticlopidine may be useful for the inhibition of PMP-dependent vascular damage in patients with connective tissue diseases complaining of peripheral circulation disorders.
No takes yet. Share an insight, caveat, or question.
Kagawa et al. (1999) conducted an observational in Connective tissue diseases with peripheral circulation disorders (n=16). Ticlopidine hydrochloride vs. Baseline (before treatment) was evaluated on Platelet-derived microparticles (PMP) and platelet CD63 levels (p=<0.01). Ticlopidine reduced platelet-derived microparticles and platelet CD63 in patients with connective tissue diseases.
Synapse has enriched 10 related papers. Consider them for comparative context: